<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1394126</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2024.1394126</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>In silico</italic> studies on leishmanicide activity of limonoids and fatty acids from <italic>Carapa guianensis</italic> Aubl</article-title>
<alt-title alt-title-type="left-running-head">de Barros et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2024.1394126">10.3389/fchem.2024.1394126</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>de Barros</surname>
<given-names>Renilson Castro</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2586154/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Araujo da Costa</surname>
<given-names>Renato</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Farias</surname>
<given-names>Suelem Daniella Pinho</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Albuquerque</surname>
<given-names>Kelly Cristina Oliveira</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marinho</surname>
<given-names>Andrey Moacir R.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Campos</surname>
<given-names>Marliane Batista</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marinho</surname>
<given-names>Patr&#xed;cia Santana Barbosa</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dolabela</surname>
<given-names>Maria Fani</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing//"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Pharmaceutical Sciences Postgraduate Program</institution>, <institution>Federal University of Par&#xe1;</institution>, <addr-line>Bel&#xe9;m</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Federal Institute of Education Sciences of the State of Par&#xe1;</institution>, <addr-line>Abaetetuba</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Faculty of Pharmacy</institution>, <institution>Federal University of Par&#xe1;</institution>, <addr-line>Bel&#xe9;m</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Biotechnology and Biodiversity Postgraduate Program (BIONORTE)</institution>, <institution>Federal University of Par&#xe1;</institution>, <addr-line>Bel&#xe9;m</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Post-Graduation in Chemistry</institution>, <institution>Federal University of Par&#xe1;</institution>, <addr-line>Bel&#xe9;m</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Leishmaniasis Laboratory</institution>, <institution>Evandro Chagas Institute</institution>, <addr-line>Ananindeua</addr-line>, <addr-line>PA</addr-line>, <country>Brazil</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/680086/overview">Anakuthil Anoop</ext-link>, Indian Institute of Technology Kharagpur, India</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1853448/overview">Rosa E. Del R&#xed;o</ext-link>, Michoacana University of San Nicol&#xe1;s de Hidalgo, Mexico</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/532732/overview">Marcus Scotti</ext-link>, Federal University of Para&#xed;ba, Brazil</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Maria Fani Dolabela, <email>fanidolabela03@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>07</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>1394126</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>07</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 de Barros, Araujo da Costa, Farias, de Albuquerque, Marinho, Campos, Marinho and Dolabela.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>de Barros, Araujo da Costa, Farias, de Albuquerque, Marinho, Campos, Marinho and Dolabela</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The oil of <italic>Carapa guianensis</italic> showed leishmanicidal activity, with its activity being related to limonoids, but fatty acids are the major constituents of this oil. The present study evaluated the physicochemical, pharmacokinetic, and toxicity profiles of limonoids and fatty acids already identified in the species. Based on these results, 2 limonoids (methyl angosinlate, 6-OH-methyl angosinlate) and 2 fatty acids (arachidic acid; myristic acid) were selected for the prediction of possible targets and molecular docking. Included in this study were: Gedunin, 6&#x3b1;-acetoxygedunin, Methyl angosenlato, 7-deacetoxy-7-oxogedunin, Andirobin, 6-hydroxy-angolensate methyl, 17&#x3b2;-hydroxyazadiradione, 1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, xyllocensin k, 11beta-Hydroxygedunin, 6&#x3b1;,11-11&#x3b2;-diacetoxygedunin, Oleic Acid, Palmitic Acid, Stearic Acid, Arachidic Acid, Myristic Acid, Palmitoleic Acid, Linoleic Acid, Linolenic Acid, and Beenic Acid. Regarding physicochemical aspects, fatty acids violated LogP, and only limonoid 11 violated Lipinski&#x2019;s rule. A common pharmacokinetic aspect was that all molecules were well absorbed in the intestine and inhibited CYP. All compounds showed toxicity in some model, with fatty acids being mutagenic and carcinogenic, and limonoids not being mutagenic and carcinogenic at least for rats. In in vivo models, fatty acids were less toxic. Molecular dockings were performed on COX-2 steroids (15 and 16) and hypoxia-inducible factor 1 alpha for limonoids (3,6), with this target being essential for the intracellular development of leishmania. Limonoids 3 and 6 appear to be promising as leishmanicidal agents, and fatty acids are promising as wound healers.</p>
</abstract>
<kwd-group>
<kwd>methyl angolensate</kwd>
<kwd>6-hydroxy-methyl angolensate</kwd>
<kwd>arachidic acid</kwd>
<kwd>myristic acid</kwd>
<kwd>COX-2</kwd>
<kwd>hypoxia-inducibke factor 1 alpha</kwd>
</kwd-group>
<contract-sponsor id="cn001">Pr&#xf3;-Reitoria de Pesquisa e P&#xf3;s-Gradua&#xe7;&#xe3;o, Universidade Federal do Par&#xe1;<named-content content-type="fundref-id">10.13039/100017425</named-content>
</contract-sponsor>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Theoretical and Computational Chemistry</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>The treatment of leishmaniasis is carried out using pentavalent antimonials, which are chemotherapeutic agents of high cost, requiring long-term treatment and capable of causing strong adverse reactions that negatively interfere with treatment adherence (<xref ref-type="bibr" rid="B27">Mann et al., 2021</xref>). Another drug is Amphotericin B (<xref ref-type="bibr" rid="B1">Aguiar and Rodrigues, 2017</xref>), which also presents similar problems to antimonials, being a high-cost and highly toxic treatment (<xref ref-type="bibr" rid="B30">Mcgwire and Satoskar, 2014</xref>; <xref ref-type="bibr" rid="B19">Falci and Pasqualotto, 2015</xref>).</p>
<p>Another issue related to leishmanicidal drugs is the increasing parasite resistance, which makes it necessary to search for pharmacological alternatives (<xref ref-type="bibr" rid="B39">Rodrigues et al., 2006</xref>). Andiroba oil (<italic>C. guianensis</italic>) is used by traditional communities for the treatment of wounds (<xref ref-type="bibr" rid="B37">Pinto, 1963</xref>). From <italic>Carapa guianensis</italic> oil, limonoids have been identified, with the main ones highlighted as: gedunin, 6&#x3b1;-acetoxygedunin, methyl angolensate, 7-deacetoxy-7-oxogedunin, andirobin, 6-hydroxymethyl angolensate, 17&#x3b2;-hydroxyazadiradione, 1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, and xylolcensin K (<xref ref-type="bibr" rid="B2">Ambrozin et al., 2006</xref>; <xref ref-type="bibr" rid="B45">Tappin et al., 2008</xref>; <xref ref-type="bibr" rid="B42">Silva et al., 2009</xref>). The metabolites in higher concentration are fatty acids (palmitic and oleic acid), followed by stearic, linoleic, linolenic, myristic, palmitoleic, and behenic acids (<xref ref-type="bibr" rid="B41">Salgado et al., 2015</xref>).</p>
<p>The seed oil of <italic>C. guianensis</italic> showed no antileishmanial activity, and the cytotoxicity was higher than 1,000&#xa0;&#x3bc;g/mL against peritoneal macrophages. The limonoid-rich oil fraction demonstrated activity against promastigotes <italic>Leishmania amazonensis</italic> (IC<sub>50</sub> &#x3d; 10.53&#xa0;&#x3bc;g/mL), amastigotes (IC<sub>50</sub> &#x3d; 27.31&#xa0;&#x3bc;g/mL), and exhibited cytotoxicity (IC<sub>50</sub> &#x3d; 78.55&#xa0;&#x3bc;g/mL) (<xref ref-type="bibr" rid="B34">Oliveira et al., 2018</xref>). In summary, the leishmanicidal activity may be related to the limonoids; however, there is a lack of data on the physicochemical, pharmacokinetic aspects, and possible mechanism of action. On the other hand, the major compounds of <italic>C. guianensis</italic> are fatty acids, and studies on these compounds are limited.</p>
<p>Using predicton methods, this work reports on the physicochemical properties, pharmacokinetics, toxicological aspects, potential activities, and targets involved of limonoids and fatty acids identified in <italic>C. guianensis</italic> oil, as well as their potential mechanisms of action involved in leishmanicidal activity.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Criteria for the selection of molecules</title>
<p>The following limonoids were selected: gedunin, 6&#x3b1;-acetoxygedunin, methyl angolensate, 7-deacetoxy-7-oxogedunin, andirobin, 6-hydroxymethyl angolensate, 17&#x3b2;-hydroxyazadiradione, 1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, xylolcensin K (<xref ref-type="bibr" rid="B2">Ambrozin et al., 2006</xref>; <xref ref-type="bibr" rid="B45">Tappin et al., 2008</xref>; <xref ref-type="bibr" rid="B42">Silva et al., 2009</xref>), 11beta-Hydroxygedunin, and 6&#x3b1;,11&#x3b2;-diacetoxygedunin (<xref ref-type="bibr" rid="B34">Oliveira et al., 2018</xref>).</p>
<p>The following fatty acids were also selected for prediction studies: oleic acid, palmitic acid, stearic acid, arachidic acid, myristic acid, palmitoleic acid, linoleic acid, linolenic acid, and behenic acid (<xref ref-type="bibr" rid="B41">Salgado et al., 2015</xref>; <xref ref-type="bibr" rid="B43">Silva, 2018</xref>).</p>
</sec>
<sec id="s2-2">
<title>2.2 In silico evaluation</title>
<p>The molecules were drawn using the <xref ref-type="bibr" rid="B28">Marvin (2023)</xref> online program (<ext-link ext-link-type="uri" xlink:href="https://marvinjs-demo.chemaxon.com/latest/demo.html">https://marvinjs-demo.chemaxon.com/latest/demo.html</ext-link>), and for the determination of physicochemical properties, the online server Home-ADMElab was used (<ext-link ext-link-type="uri" xlink:href="https://admet.scbdd.com/">https://admet.scbdd.com</ext-link>) (<xref ref-type="bibr" rid="B15">Dong, 2024</xref>). The Lipinski&#x2019;s Rule of Five or &#x201c;Rule of Five&#x201d; was considered (<xref ref-type="bibr" rid="B24">Lipinski, 2004</xref>). For pharmacokinetic and toxicity predictions, the PreADMET program (version 2.0, Copyright <sup>&#xa9;</sup> 2005&#x2013;2017) was used, which considers pharmacokinetic properties (A&#x2013;absorption; D&#x2013;Distribution; M&#x2013;Metabolism/Biotransformation; E&#x2013;Excretion) and evaluation of toxicity parameters (T&#x2013;Toxicity; <xref ref-type="bibr" rid="B38">Preadmet, 2020</xref>).</p>
<p>For the assessment of toxicity in marine organisms, the criteria used were as follows: for toxicity in algae (<xref ref-type="bibr" rid="B10">Costa et al., 2008</xref>); for Daphnia sp (<xref ref-type="bibr" rid="B20">Guilhermino et al., 2000</xref>); for Medaka (<xref ref-type="bibr" rid="B50">Zucker, 1985</xref>); and for Minnow (<xref ref-type="bibr" rid="B10">Costa et al., 2008</xref>). The mutagenicity risk was assessed by the Ames test with the following strains of <italic>Samonella Typhimurium:</italic> TA100-10RLI and TA 100-NA mutation in His G46e plasmid pKM101 without S9; TA1535- 10RLI and TA1535-NA mutation in His G46 (<xref ref-type="bibr" rid="B3">Ames et al., 1975</xref>). The carcinogenic potential of the compounds was evaluated in rats and mice and referred to as (&#x2b;) carcinogenic and (&#x2212;) non-carcinogenic. To predict acute oral toxicity (lethal dose 50%- LD<sub>50</sub>), the online software PROTOX II was used (<xref ref-type="bibr" rid="B17">Drwal et al., 2014</xref>), considering the classification from I to VI, according to ABNT NBR 14725-2 (2019). Adverse events that may occur with the use of the molecule were also evaluated.</p>
<p>The search for potential targets for molecular docking prediction was conducted using the SuperPred Webserver program (<xref ref-type="bibr" rid="B32">Nickel et al., 2014</xref>), a server for predicting molecular targets with potential interaction with the investigated ligands. The targets, which showed relevance to the investigated biological activity, were obtained from the Protein Data Bank database (PDB ID 4H6J and <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=5F19&#x26;template=3Dmoljsbox.html">5F19</ext-link>/4OTY). Compounds with the highest scores for therapeutic activity (&#x2265;70% probability of binding and &#x2265;70% prediction accuracy) were selected for molecular docking simulations.</p>
</sec>
<sec id="s2-3">
<title>2.3 Docking molecular</title>
<p>Molecular targets were determined: Hypoxia-inducible factor 1 alpha (HIF-1-&#x3b1;, PDB 4H6J) and Cyclooxygenase-2 (COX-2, PDB <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=5F19&#x26;template=3Dmoljsbox.html">5F19</ext-link>/4OTY). The crystallographic structure of the enzymes was retrieved from the Protein Data Bank (PDB) under the codes 4H6J (<xref ref-type="bibr" rid="B6">Cardoso et al., 2012</xref>) with a resolution of 1.52 &#x212b; and 4OTY with a resolution of 2.35 &#x212b;.</p>
<p>The structures of the compounds were initially obtained from PubChem (<ext-link ext-link-type="uri" xlink:href="http://pubchem.org">http://pubchem.org</ext-link>) in sdf format. OpenBabel (<xref ref-type="bibr" rid="B33">O&#x2019;Boyle et al., 2011</xref>) was used to generate the 3D coordinates of the compounds and optimized using the Gaussian 09 software. Docking molecular simulations were conducted using the program Molegro Virtual Docker (MVD) version 5.5 (<xref ref-type="bibr" rid="B5">Bitencourt-Ferreira and de Azevedo, 2019</xref>).</p>
<p>Redocking was performed using the inhibitor lumiracoxib (LUR) of the COX-2 protein (PDB 4OTY). The enzyme&#x2019;s active site was defined as a spherical region of 12&#xa0;&#xc5;, based on the coordinates of the crystallographic ligand lumiracoxib using the MolDock Score scoring function.</p>
<p>For HIF-1-&#x3b1;, due to the absence of a crystallized inhibitor, data from the literature and the cavity detector of the program (<xref ref-type="bibr" rid="B44">Singh et al., 2023</xref>; <xref ref-type="bibr" rid="B22">Kong et al., 2022</xref>) and the cavity detector of the MVD with coordinates x: 6.35, y: &#x2212;26.39, z: &#x2212;22.37 and a sphere of 12&#xa0;&#xc5; were used. Ligands underwent 10 iterative runs, and the pose with the best scoring result was considered for the analysis of intermolecular interactions using the Discovery Studio Visualizer (<xref ref-type="bibr" rid="B14">Discovery Studio Visualizer Dassault Syst&#xe8;mes BIOVIA, 2021</xref>).</p>
</sec>
<sec id="s2-4">
<title>2.4 Molecular dynamics (MD)</title>
<p>The stability of the ligand-receptor complexes for the apo form of HIF-1alpha and its form complexed with molecules 3, 6, and the reference inhibitor lificiguat (YC-1) was analyzed. Also, the apo form of COX-2 complexed with molecules 15, 16, and the reference inhibitor lumiracoxib. The AMBER22 simulation package was used to perform 200 ns MD simulations on all complexes prepared using the GPU-accelerated version of the Particle Mesh Ewald Molecular Dynamics (PMEMD) (<xref ref-type="bibr" rid="B23">Lee et al., 2018</xref>).</p>
<p>Proteins and ligands were prepared in ff14SB (<xref ref-type="bibr" rid="B26">Maier et al., 2015</xref>) and GAFF (<xref ref-type="bibr" rid="B48">Wang et al., 2004</xref>), with atomic charges calculated using the restrained electrostatic potential (RESP) protocol at the HF/6-31G&#x2a;25 theoretical level using the Gaussian 09 software. The protonation states of the ionizable residues were analyzed by calculating the pKa at neutral pH using the PDB2PQR server (<xref ref-type="bibr" rid="B16">Dolinsky et al., 2007</xref>). All systems were solvated in the tLeap module using an octahedral water box with the TIP3P model (<xref ref-type="bibr" rid="B21">Jorgensen et al., 1983</xref>). Na &#x2b; ions were added to maintain the system&#x2019;s electroneutrality. Each step was performed by applying steps of steepest descent minimization followed by 5,000 of conjugated gradient.</p>
<p>The systems were heated from 0 to 300&#xa0;K, maintained at 300&#xa0;K (Langevin thermostat), performing 200 ps of MD and 300 ps of density equilibration, and 500 ps without positional restraints at constant pressure. A cutoff point of 10&#xa0;&#xc5; for the systems was used for non-bonded interactions, the Particle Mesh Ewald (PME) method (<xref ref-type="bibr" rid="B36">Petersen, 1995</xref>), and the SHAKE algorithm (<xref ref-type="bibr" rid="B18">Elber, 2011</xref>) were used to restrict bond lengths involving hydrogen atoms. Finally, MD (production) simulations were performed using 200 ns at a temperature of 300&#xa0;K without positional restraints. The deviations of the protein and protein-ligand complex systems were analyzed by calculating the root mean square deviation (RMSD), root mean square fluctuation (RMSF), and hydrogen bonds using the CPPTRAJ module (<xref ref-type="bibr" rid="B40">Roe and Cheatham, 2013</xref>).</p>
</sec>
<sec id="s2-5">
<title>2.5 Binding free energy calculation using MM/GBSA</title>
<p>The MM/GBSA technique accurately calculates the total binding free energy of protein-ligand complexes using the AmberTools23 package (<xref ref-type="bibr" rid="B11">Da Costa et al., 2022</xref>; <xref ref-type="bibr" rid="B7">Case et al., 2023</xref>). The last 10 ns of the MD simulation trajectories were used to calculate the binding free energy.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 In silico evalution</title>
<p>All limonoids already isolated from <italic>C. guianensis</italic> were included in this study. Similarly, identified fatty acids of the species were selected (<xref ref-type="fig" rid="F1">Figure 1</xref>):</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Main Limonoids and fatty acids isolated from <italic>Carapa guianensis</italic> oil. 1 - Gedunin, 2 - 6&#x3b1;-acetoxygedunin, 3 - Methyl angolensate, 4 - 7-deacetoxy-7-oxogedunin, 5 - Andirobin, 6 - 6-hydroxy-methyl angolensate, 7&#x2013;17&#x3b2;-hydroxyazadiradione, 8&#x2013;1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, 9 - Xylocensin K, 10&#x2013;11beta-Hydroxygedunin, 6 &#x3b1;, 11&#x2013;11&#x3b2;-diacetoxygedunin, 12 - Oleic acid, 13 - Palmitic acid, 14 - Stearic acid, 15 - Arachidic acid, 16 - Myristic acid, 17 - Palmitoleic acid, 18 - Linoleic acid, 19 - Linolenic acid, 20 - Behenic acid.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g001.tif"/>
</fig>
<p>Regarding the predictions of the physicochemical characteristics of the fatty acids (12, 13, 14, 15, 17, 18, 19, and 20), they demonstrated a partition coefficient oil-water (LogP) higher than 5.0, while the limonoids have higher molecular masses (MM), with limonoid 11 violating the Lipinski&#x2019;s rule. Molecule 2 showed only one violation in molecular mass (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Prediction of physicochemical properties.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Molecules</th>
<th align="left">MM</th>
<th align="left">LogP</th>
<th align="center">TPSA</th>
<th align="left">nHBA</th>
<th align="left">nHBD</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="left">482.57</td>
<td align="left">4.56</td>
<td align="center">95.34</td>
<td align="center">7</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">2</td>
<td align="left">540.00</td>
<td align="left">4.10</td>
<td align="center">121.64</td>
<td align="center">9</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">3</td>
<td align="left">470.56</td>
<td align="left">4.56</td>
<td align="center">92.04</td>
<td align="center">7</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">4</td>
<td align="left">438.52</td>
<td align="left">4.19</td>
<td align="center">86.11</td>
<td align="center">6</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">5</td>
<td align="left">468.54</td>
<td align="left">4.33</td>
<td align="center">95.34</td>
<td align="center">7</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">6</td>
<td align="left">486.56</td>
<td align="left">3.35</td>
<td align="center">112.27</td>
<td align="center">8</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">7</td>
<td align="left">466.57</td>
<td align="left">4.52</td>
<td align="center">93.81</td>
<td align="center">6</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">8</td>
<td align="left">442.55</td>
<td align="left">4.21</td>
<td align="center">89.27</td>
<td align="center">6</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">9</td>
<td align="left">486.56</td>
<td align="left">3.36</td>
<td align="center">112.27</td>
<td align="center">8</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">10</td>
<td align="left">498.52</td>
<td align="left">3.53</td>
<td align="center">115.57</td>
<td align="center">8</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">11</td>
<td align="left">598.64</td>
<td align="left">3.64</td>
<td align="center">147.94</td>
<td align="center">11</td>
<td align="center">0</td>
</tr>
<tr>
<td align="center">12</td>
<td align="left">282.46</td>
<td align="left">6.10</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">13</td>
<td align="left">256.43</td>
<td align="left">5.55</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">14</td>
<td align="left">284.48</td>
<td align="left">6.33</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">15</td>
<td align="left">312.53</td>
<td align="left">7.11</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">16</td>
<td align="left">228.37</td>
<td align="left">4.77</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">17</td>
<td align="left">254.41</td>
<td align="left">5.32</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">18</td>
<td align="left">280.45</td>
<td align="left">5.88</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">19</td>
<td align="left">278.43</td>
<td align="left">5.66</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="center">20</td>
<td align="left">340.59</td>
<td align="left">7.89</td>
<td align="center">37.30</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Lipinski&#x2019;s rule: LogP - oil-water partition coefficient &#x2264;5; TPSA: topological polar surface area &#x2264;140&#xa0;&#xc5;; nHBA: number of hydrogen bond acceptors &#x2264;10; nHBD: number of hydrogen bond donor groups &#x2264;5; MM, molecular mass &#x2264;500D (<xref ref-type="bibr" rid="B24">Lipinski, 2004</xref>). 1 - Gedunin, 2 - 6&#x3b1;-acetoxygedunin, 3 - Methyl angolensate, 4 - 7-deacetoxy-7-oxogedunin, 5 - Andirobin, 6 - 6-hydroxy-methyl angolensate, 7&#x2013;17&#x3b2;-hydroxyazadiradione, 8&#x2013;1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, 9 - Xylocensin K, 10&#x2013;11beta-Hydroxygedunin, 6 &#x3b1;, 11&#x2013;11&#x3b2;-diacetoxygedunin, 12 - Oleic acid, 13 - Palmitic acid, 14 - Stearic acid, 15 - Arachidic acid, 16 - Myristic acid, 17 - Palmitoleic acid, 18 - Linoleic acid, 19 - Linolenic acid, 20 - Behenic acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Despite the compounds&#x2019; permeability ranging from low to high, all molecules appear to be well absorbed in the gastrointestinal tract. Regarding distribution, molecules 2, 5, 6, 9, 10, and 11 exhibit reduced plasma protein binding and moderate distribution to the central nervous system (CNS), except molecule 6, which showed low distribution. Only the fatty acids distribute highly to the CNS, likely due to their high lipid solubility (<xref ref-type="bibr" rid="B8">Chagas et al., 2022</xref>). All limonoids inhibit CYP2C9 and CYP3A4, with CYP3A4 being the main enzyme involved in the metabolism of these molecules. Fatty acids are inhibited by CYP2C19, CYP2C9, and CYP3A4 and do not undergo phase 1 metabolism (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Prediction of pharmacokinetic properties.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th colspan="2" align="left"/>
<th colspan="2" align="left">Absorption</th>
<th colspan="2" align="left">Distribution</th>
<th colspan="2" align="center">Metabolism</th>
</tr>
<tr>
<th align="left">Molecules</th>
<th align="center">MDCK</th>
<th align="center">Caco 2</th>
<th align="center">HIA</th>
<th align="center">PP</th>
<th align="center">BBB</th>
<th align="center">CYP Inibition</th>
<th align="center">CYP phase 1</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">F</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">F</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">F</td>
<td align="center">L</td>
<td align="center">2C9,3A4</td>
<td align="center">3A4</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">L</td>
<td align="center">2C9,3A4</td>
<td align="center">CYP3A4</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">L</td>
<td align="center">2C9,3A4</td>
<td align="center">CYP3A4</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">F</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">CYP3A4</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">L</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">F</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">CYP3A4</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">F</td>
<td align="center">M</td>
<td align="center">2C9,3A4</td>
<td align="center">CYP3A4</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">H</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">H</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">H</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">18</td>
<td align="center">H</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">19</td>
<td align="center">H</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">20</td>
<td align="center">M</td>
<td align="center">M</td>
<td align="center">H</td>
<td align="center">S</td>
<td align="center">H</td>
<td align="center">2C19,2C9,3A4</td>
<td align="center">-</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>BBB: blood-brain barrier; CYP: cytochrome P450; HIA: human intestinal absorption, S&#x2a;: strongly; F&#x2a;: freely; NO: not observed; W: weakly; H: high; L: low; M: medium; 1 - Gedunin, 2 - 6&#x3b1;-acetoxygedunin, 3 - Methyl angolensate, 4 - 7-deacetoxy-7-oxogedunin, 5 - Andirobin, 6 - 6-hydroxy-methyl angolensate, 7&#x2013;17&#x3b2;-hydroxyazadiradione, 8&#x2013;1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, 9 - Xylocensin K, 10&#x2013;11beta-Hydroxygedunin, 6 &#x3b1;, 11&#x2013;11&#x3b2;-diacetoxygedunin, 12 - Oleic acid, 13 - Palmitic acid, 14 - Stearic acid, 15 - Arachidic acid, 16 - Myristic acid, 17 - Palmitoleic acid, 18 - Linoleic acid, 19 - Linolenic acid, 20 - Behenic acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The toxicity prediction model showed a limitation regarding molecule 11, for which it was not possible to determine the toxicity parameters. All compounds were toxic to algae, Daphnia, and Medaka and Minnow fishes. Regarding mutagenicity, the fatty acids were mutagenic for strain TA1535_NA. The fatty acids were carcinogenic for rats and mice. Except for acids 13, 14, 15, and 16, which were not carcinogenic for mice. The limonoids were not mutagenic, but they were carcinogenic for rats and mice, except for 3, 6, and 8, which were not carcinogenic for mice (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Prediction of toxicity.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th rowspan="2" align="center">Molecules</th>
<th rowspan="2" align="center">Alga</th>
<th rowspan="2" align="center">Daphnia</th>
<th colspan="2" align="center">Fish</th>
<th rowspan="2" align="center">Ames</th>
<th align="center">Carcino</th>
</tr>
<tr>
<th align="center">Medaka</th>
<th align="center">Minnow</th>
<th align="center">Rats/Mice</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">N</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">-</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/N</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">18</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">19</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/P</td>
</tr>
<tr>
<td align="center">20</td>
<td align="center">T</td>
<td align="center">T</td>
<td align="center">VT</td>
<td align="center">VT</td>
<td align="center">1535-NA</td>
<td align="center">P/P</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>T: toxic; NT: non-toxic; N: negative; P: positive. Parameters: Algae - &#x3c; 1&#xa0;mg/L toxic; &#x3e;1&#xa0;mg/L non-toxic (<xref ref-type="bibr" rid="B10">Costa, et al., 2008</xref>); Daphnia Test: &#x3c;0.22&#xa0;&#x3bc;g/mL toxic; &#x3e;0.22&#xa0;&#x3bc;g/mL - non-toxic (<xref ref-type="bibr" rid="B20">Guilhermino, et al., 2000</xref>); Test on Medaka and Minnow fish: &#x3c;1&#xa0;mg/L - very toxic; 1&#x2013;10 mg/L-toxic; 10&#x2013;100 mg/L-harmful and &#x3e;100 mg/L-extremely toxic (<xref ref-type="bibr" rid="B50">Zucker, 1985</xref>), Carcino Rat/mice&#x2a; &#x3d; carcinogenicity in rat/mice. T-toxic, NT-non-toxic, VT-very toxic, N-negative, P-positive. 1 - Gedunin, 2 - 6&#x3b1;-acetoxygedunin, 3 - Methyl angolensate, 4 - 7-deacetoxy-7-oxogedunin, 5 - Andirobin, 6 - 6-hydroxy-methyl angolensate, 7&#x2013;17&#x3b2;-hydroxyazadiradione, 8&#x2013;1,2-dihydro-3&#x3b2;-hydroxy-7-deacetoxy-7-oxogedunin, 9 - Xylocensin K, 10&#x2013;11beta-Hydroxygedunin, 6 &#x3b1;, 11&#x2013;11&#x3b2;-diacetoxygedunin, 12 - Oleic acid, 13 - Palmitic acid, 14 - Stearic acid, 15 - Arachidic acid, 16 - Myristic acid, 17 - Palmitoleic acid, 18 - Linoleic acid, 19 - Linolenic acid, 20 - Behenic acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Regarding acute oral toxicity, the molecules with the lowest toxic potential are the fatty acids (Class V and VI); however, despite being considered of low toxicity (Class IV), the limonoids appear to have a lower potential for side effects (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Prediction of oral toxicity.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Molecules</th>
<th align="center">LD<sub>50</sub> (mg/kg)</th>
<th align="center">Toxicity class</th>
<th align="center">Side effects</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">980</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">1,004</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">846</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">596</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">1,219</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">1,162</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">496</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">696</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">676</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">10</td>
<td align="center">559</td>
<td align="center">IV</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">11</td>
<td align="center">-</td>
<td align="center">-</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">12</td>
<td align="center">5,302</td>
<td align="center">VI</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">13</td>
<td align="center">4,010</td>
<td align="center">V</td>
<td align="center">I/T</td>
</tr>
<tr>
<td align="center">14</td>
<td align="center">4,499</td>
<td align="center">V</td>
<td align="center">I/T/M</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">4,867</td>
<td align="center">V</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">3,033</td>
<td align="center">V</td>
<td align="center">I/M</td>
</tr>
<tr>
<td align="center">17</td>
<td align="center">4,906</td>
<td align="center">V</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">18</td>
<td align="center">5,259</td>
<td align="center">VI</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">19</td>
<td align="center">6,838</td>
<td align="center">VI</td>
<td align="center">N</td>
</tr>
<tr>
<td align="center">20</td>
<td align="center">5,228</td>
<td align="center">VI</td>
<td align="center">N</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>LD50 - lethal dose 50%. NO, nothing observed. I - Irritant, T - Tumorigenic, M - Mutagenicity. Category I: 1&#x3c; LD50&#x2264; 5&#xa0;mg/kg - Extremely Toxic; Category II: 5 &#x3c; LD50 &#x2264; 50mg/kg- Highly Toxic; Category III: 50 &#x3c; LD50 &#x2264; 300&#xa0;mg/kg - Moderately Toxic; Category IV: 300 &#x3c; LD50 &#x2264; 2,000&#xa0;mg/kg - Low Toxic; Category V: 2000 &#x3c; LD50 &#x2264; 5,000 Unlikely to Cause Acute Damage; Category VI: DL50 &#x3e; 5,000 No damage. Source: ABNT NBR, 2009; RDC, No. 294, 2019. 1 - Gedunin, 2 - 6&#x3b1;-acetoxygedunin, 3 - Methyl angolensate, 4 - 7-desacetoxy-7-oxogedunin, 5 - Andirobin, 6 - 6-hydroxy-methyl angolensate, 7&#x2013;17&#x3b2;-hydroxyazadiradione, 8&#x2013;1,2-dihydro-3&#x3b2;-hydroxy-7-desacetoxy-7-oxogedunin, 9 - Xylocensin K, 10&#x2013;11beta-Hydroxygedunin, 6&#x3b1;, 11&#x2013;11&#x3b2;-diacetoxygedunin, 12 - Oleic Acid, 13 - Palmitic Acid, 14 - Stearic Acid, 15 - Arachidic Acid, 16 - Myristic Acid, 17 - Palmitoleic Acid, 18 - Linoleic Acid, 19 - Linolenic Acid, 20 - Behenic Acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Based on the predictions related to physicochemical, pharmacokinetic, and toxicity parameters, the molecules considered most promising were 3, 6, 15, 16. Subsequently, the targets with potential for biological activity related to Leishmania were determined (Hypoxia-inducible factor 1 alpha, Cyclooxygenase-2) with a probability of correctness and accuracy greater than 70%, and PDB (Protein Data Bank) code (4H6J and 5F19/4OTY) for docking, obtained through the online server as demonstrated in <xref ref-type="table" rid="T5">Table 5</xref>.</p>
<table-wrap id="T5" position="float">
<label>TABLE 5</label>
<caption>
<p>Molecular target assessment.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Molecules</th>
<th align="center">Probability (%)</th>
<th align="center">Prediction accuracy (%)</th>
<th align="center">Target Name</th>
<th align="center">PDB</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">3</td>
<td align="center">99.05</td>
<td align="center">85.14</td>
<td align="center">Hypoxia-inducible factor 1 alpha</td>
<td align="center">
<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=4H6J&#x26;template=3Dmoljsbox.html">4H6J</ext-link>
</td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">95.62</td>
<td align="center">85.14</td>
<td align="center">Hypoxia-inducible factor 1 alpha</td>
<td align="center">4H6J</td>
</tr>
<tr>
<td align="center">15</td>
<td align="center">90.73</td>
<td align="center">89.63</td>
<td align="center">Cyclooxygenase-2</td>
<td align="center">
<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=5F19&#x26;template=3Dmoljsbox.html">5F19</ext-link>/4OTY</td>
</tr>
<tr>
<td align="center">16</td>
<td align="center">90.93</td>
<td align="center">89.63</td>
<td align="center">Cyclooxygenase-2</td>
<td align="center">
<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=5F19&#x26;template=3Dmoljsbox.html">5F19</ext-link>/4OTY</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>PDB: Protein Data Bank 3- Methyl angolensate, 6 - 6-hydroxy-methyl angolensate, 15 - Arachidic Acid, 16 - Myristic Acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-2">
<title>3.2 Docking molecular simulation</title>
<p>In the redocking with the lumiracoxib (LUR) inhibitor of the COX-2 protein (PDB 4OTY), it was found that the redocked conformation of the ligand perfectly overlapped with the co-crystallized ligand, with an RMSD value of 0.33&#xa0;&#xc5; and satisfactory precision in repositioning the LUR ligand within the active site of COX-2. The RMSD value between the docking pose and the crystallographic ligand pose is less than 2.0&#xa0;&#xc5; (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Validation of molecular docking protocols using the MVD program. White is the co-crystal ligand and red is the coupling pose.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g002.tif"/>
</fig>
<p>The validated docking protocol was subsequently used for molecular docking simulation. Comparing the bindings of compounds 3 and 6 to the enzyme Hypoxia-inducible factor 1 (HIF1A), it is observed that compound 3 bound with lower energy and had a lower inhibition constant than 6. Regarding compounds 15 and 16 with Cyclooxygenase-2 (COX2), despite the low binding energy, the inhibition constants were higher than those of 3 and 6, with 16 being very high (<xref ref-type="table" rid="T6">Table 6</xref>).</p>
<table-wrap id="T6" position="float">
<label>TABLE 6</label>
<caption>
<p>Values of the binding energies between the limonoids and HIF1A.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Molecules</th>
<th align="left">&#x394;<italic>E</italic>
<sub>ele</sub>
</th>
<th align="left">&#x394;<italic>E</italic>
<sub>vdW</sub>
</th>
<th align="left">&#x394;<italic>G</italic>
<sub>GB</sub>
</th>
<th align="left">&#x394;<italic>G</italic>
<sub>SA</sub>
</th>
<th align="left">&#x394;<italic>G</italic>
<sub>bind</sub>
</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">YC-1</td>
<td align="left">&#x2212;10.18</td>
<td align="left">&#x2212;36.79</td>
<td align="left">21.13</td>
<td align="left">&#x2212;4.62</td>
<td align="center">&#x2212;30.47</td>
</tr>
<tr>
<td align="center">3</td>
<td align="left">&#x2212;19.07</td>
<td align="left">&#x2212;31.24</td>
<td align="left">33.86</td>
<td align="left">&#x2212;4.09</td>
<td align="center">&#x2212;20.56</td>
</tr>
<tr>
<td align="center">6</td>
<td align="left">&#x2212;11.69</td>
<td align="left">&#x2212;20.45</td>
<td align="left">23.51</td>
<td align="left">&#x2212;2.69</td>
<td align="center">&#x2212;11.32</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Caption: YC-1, lificiguat, 3- Methyl angolensate, 6 - 6-hydroxy-methyl angolensate.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Regarding the interactions established between the limonoids and the HIF1A protein, compound 3 did not have any unfavorable bonds, establishing alkyl bonds and hydrogen bonding. Compound 6 presented 1 unfavorable bond, 1 alkyl bond, 1&#xa0;C-H bond, and 4 hydrogen bonds (<xref ref-type="fig" rid="F2">Figure 2</xref>). Evaluating the interactions established by the fatty acids and the COX-2 protein, unfavorable bonds are observed for both compounds, with hydrogen bonds, alkyl bonds, and C-H bonds also being observed (<xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Representation of 2D interactions of molecules 3, 6, 15, 16 and inibidores YC-1, LUR. Image generated with Discovery Studio 3.5 Visualizer.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 Molecular dynamics simulation</title>
<sec id="s3-3-1">
<title>3.3.1 Interactions of the limonoids methyl angolensate and 6-hydroxy-methyl angolensate with HIF1A</title>
<p>
<xref ref-type="fig" rid="F4">Figure 4</xref> shows the RMSDs of HIF1A complexed with ligands 3, 6, and YC-1, displaying stable dynamic behavior and RMSD values of 1.87&#xa0;&#xc5; (molecule 3), 1.55&#xa0;&#xc5; (molecule 6), 1.71&#xa0;&#xc5; (YC-1), and 1.61&#xa0;&#xc5; (HIF1A-6).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Comparisons of RMSD and RMSF of the limonoids and HIF1A as a function of time and amino acid residues. YC-1 - lificiguat, 3 - Methyl angolensate, 6 - 6-hydroxy-methyl angolensate.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g004.tif"/>
</fig>
<p>
<xref ref-type="fig" rid="F5">Figure 5</xref> shows that all complexes formed by molecules 3, 6, and the YC-1 inhibitor exhibited similar behaviors, with minimal fluctuations below 2&#xa0;&#xc5;, except in the regions between residues 344-346, which showed greater fluctuation and the presence of a significant number of H bonds, suggesting a strong interaction between a ligand-protein complex.</p> <fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>RMSD and hydrogen bonds between HIF1A and the YC-1 inhibitor and molecules 3 and 6.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g005.tif"/>
</fig>
<p>In <xref ref-type="table" rid="T6">Table 6</xref>, it can be observed that molecule 3 showed the most favorable binding affinity to the HIF1A protein (&#x394;Gbind &#x2212;20.56&#xa0;kcal/mol), compared to molecule 6 (&#x394;Gbind &#x2212;11.32&#xa0;kcal/mol).</p>
</sec>
<sec id="s3-3-2">
<title>3.3.2 Interactions of fatty acids with COX-2</title>
<p>When comparing the RMSD values over time, it is observed that molecules 15 and 16 exhibit lower values than LUR (<xref ref-type="fig" rid="F6">Figure 6</xref>). Regarding the comparison of RMSD and amino acid residues, in most bonds, proximities were observed between this parameter; however, the lowest RMSD values were observed for molecule 16 (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Comparisons of RMSD in the binding of fatty acids and COX-2 as a function of time and amino acid residues.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g006.tif"/>
</fig>
<p>Regarding the ligand&#x2019;s ability to establish hydrogen bonds with COX-2, a greater number of bonds between the protein and molecule 15 were observed (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>RMSD and hydrogen bonds between COX-2, LUR, and molecules 15 and 16.</p>
</caption>
<graphic xlink:href="fchem-12-1394126-g007.tif"/>
</fig>
<p>In <xref ref-type="table" rid="T7">Table 7</xref>, it can be observed that molecule 15 showed the most favorable binding affinity to the COX-2 protein (&#x394;Gbind - 54.36&#xa0;kcal/mol), compared to molecule 16 (&#x394;Gbind - 35.90&#xa0;kcal/mol).</p>
<table-wrap id="T7" position="float">
<label>TABLE 7</label>
<caption>
<p>Values of the binding energies between fatty acids and COX-2.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Molecules</th>
<th align="left">&#x394;Eele</th>
<th align="left">&#x394;EvdW</th>
<th align="left">&#x394;GGB</th>
<th align="left">&#x394;GSA</th>
<th align="left">&#x394;Gbind</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">LUR</td>
<td align="left">&#x2212;37.76</td>
<td align="left">&#x2212;35.77</td>
<td align="left">44.42</td>
<td align="left">&#x2212;5.34</td>
<td align="left">&#x2212;34.46</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">&#x2212;7.34</td>
<td align="left">&#x2212;59.96</td>
<td align="left">21.55</td>
<td align="left">&#x2212;8.61</td>
<td align="left">&#x2212;54.36</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">&#x2212;11.89</td>
<td align="left">&#x2212;40.82</td>
<td align="left">22.82</td>
<td align="left">&#x2212;6.01</td>
<td align="left">&#x2212;35.90</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Caption: LUR-lumiracoxib, 15 - Arachidic Acid, 16 - Myristic Acid.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>4 Discussion</title>
<p>This study evaluated the physicochemical, pharmacokinetic, and toxicity aspects of fatty acids already identified in <italic>C. guianensis</italic> Oil, observing in the physicochemical study that they violate the LogP. The LogP assesses the balance between liposolubility and hydrosolubility, and when it is above 5, it can be a predictive factor for low absorption of the compounds in the gastrointestinal tract. However, pharmacokinetic prediction studies demonstrated that in MDCK cells, the permeability of the compounds was moderate to high, while in Caco2 cells, the permeability was moderate. The high permeability in MDCK cells suggests that these compounds may be absorbed by passive diffusion (<xref ref-type="bibr" rid="B9">Chen et al., 2018</xref>). That is, they can cross the lipid layer due to their high liposoluble potential. The permeability in Caco2 cells evaluates absorption in the Colon region, which seems to be moderate, and perhaps, the high intestinal absorption of these compounds may occur due to absorption in different locations of the GI tract (<xref ref-type="bibr" rid="B12">Da Silva Miranda et al., 2022</xref>).</p>
<p>Due to their MM &#x3c; 500D and high liposolubility, the evaluated fatty acids appear to freely cross the blood-brain barrier. Therefore, therapeutic concentrations can be achieved centrally and peripherally, expanding their medicinal potential. However, adverse reactions may occur centrally and peripherally. Additionally, these compounds strongly bind to plasma protein and appear not to be metabolized by CYP. It is worth noting that phase 1 metabolism makes the compound more polar and facilitates renal excretion. It is important to emphasize that fatty acids play an essential role in the body, from strengthening immunity to their importance in the inflammatory response (<xref ref-type="bibr" rid="B35">Pereira, 2008</xref>).</p>
<p>A concerning point in terms of pharmacokinetics is the inhibitory potential of CYP2C19, CYP2C9, and CYP3A4, which may interfere with the metabolism of other drugs. Since CYP3A4 metabolizes a large number of drugs, its inhibition can lead to an increase in the plasma concentration of these drugs and elevate the risk of toxic effects.</p>
<p>Another important aspect evaluated was the toxicity of fatty acids in algae, crustaceans, and fish. All fatty acids were toxic to algae and crustaceans, while they were not toxic to fish. The model for algae is used to predict acute oral toxicity in terms of mortality (<xref ref-type="bibr" rid="B20">Guilhermino et al., 2000</xref>). The Daphnia crustacean model is used to predict acute and subchronic toxicities. The model for Medaka and Minnow fish suggests acute and subchronic toxicity, as well as changes in different organs (<xref ref-type="bibr" rid="B4">Bauer, 2017</xref>).</p>
<p>All fatty acids showed mutagenic potential (TA1535-NA), with mutations potentially occurring in both somatic and germline cells, depending on the genes, which may or may not have phenotypic effects, potentially leading to severe clinical consequences. Additionally, compounds 12, 17, 18, 19, and 20 were found to have carcinogenic potential in rats and mice, with carcinogenesis involving the conversion of a normal cell into a malignant cell, requiring prolonged time and repeated exposure to carcinogens (<xref ref-type="bibr" rid="B25">Loureiro et al., 2002</xref>). Thus, if used acutely or for short periods, the carcinogenic potential of fatty acids is minimized.</p>
<p>Regarding acute oral toxicity, the molecules with the lowest toxic potential are the fatty acids (Class V and VI). However, molecules 13, 14, and 16 appear to have side effects related to irritation, tumorigenicity, and mutagenicity. Therefore, while fatty acids may not be lethal when ingested, the side effects on organisms are a trade-off of these results, requiring attention to these molecules despite limited toxicity studies.</p>
<p>The limonoids, except for 11, followed the Lipinski rule; however, their permeability in MDCK cells showed that only one molecule had high permeability, suggesting that the mechanism used in cellular diffusion may not be passive diffusion (<xref ref-type="bibr" rid="B9">Chen et al., 2018</xref>). Additionally, the results in Caco2 cells showed moderate permeability, suggesting that absorption in the intestine occurs at more than one location, thus explaining the high intestinal absorption. However, limonoids have higher molecular mass (MM) compared to fatty acids, but only molecule 2 has a molecular mass (MM) exceeding 500D. On the other hand, molecule 11 violated the Lipinski rule. Despite limited oral bioavailability in molecules that do not adhere to Lipinski&#x2019;s rule, the therapeutic potential should not be ignored (<xref ref-type="bibr" rid="B24">Lipinski, 2004</xref>).</p>
<p>Similarly to fatty acids, limonoids exhibited high intestinal absorption, despite low to moderate permeability in MDCK and moderate permeability in Caco2. These results suggest that perhaps the diffusion mechanism through membranes is not passive and that their absorption may occur in other intestinal regions (<xref ref-type="bibr" rid="B9">Chen et al., 2018</xref>). Another similarity with fatty acids was the potential inhibitory effect on CYPs, which could interfere with the metabolism of different classes of drugs (<xref ref-type="bibr" rid="B9">Chen et al., 2018</xref>).</p>
<p>In terms of toxicity, the significant advantage of limonoids over fatty acids is that they did not show mutagenic potential in predictions. A previous study demonstrated that limonoids found in andiroba oil have anti-inflammatory, anticancer, antitumor, and antiallergic properties (<xref ref-type="bibr" rid="B29">Matsui et al., 2014</xref>; Higuchi et al., 2017; <xref ref-type="bibr" rid="B46">Tsukamoto, 2019</xref>).</p>
<p>One disadvantage of limonoids compared to fatty acids was their higher acute oral toxicity, with their simulated LD50 belonging to class IV. However, it is important to establish the effective dose 50% of limonoids, thus allowing the determination of the therapeutic window of these compounds, ensuring their safety of use. On the other hand, there were no results related to side effects, which is encouraging for the possibility of a promising drug (<xref ref-type="bibr" rid="B31">Miranda-J&#xfa;nior et al., 2012</xref>).</p>
<p>The molecular docking studies of the selected limonoids and fatty acids were conducted against molecular targets of Leishmania, aiming to explore their leishmanicidal potential. These enzymes are necessary for the parasite&#x2019;s survival and represent relevant targets for the development of new drugs (<xref ref-type="bibr" rid="B13">Degrossoli et al., 2007</xref>). The limonoids exhibited the best characteristics and molecular affinities, as they formed hydrogen bonds with the Tyr254 residue, which participates in the active site, potentially generating irreversible inhibitors (<xref ref-type="bibr" rid="B6">Cardoso et al., 2012</xref>). Comparing the two limonoids and their binding to HIF1A, it can be suggested that limonoid 3 established a better binding.</p>
<p>Regarding fatty acids and their binding to cyclooxygenase 2, inhibition of which is related to anti-inflammatory effects, molecules 15 and 16 bound with favorable binding energy, but 16 had a very unfavorable inhibition constant. Thus, the more promising molecule was 15, which may contribute to the treatment of cutaneous leishmaniasis in the wound healing phase. This process involves interaction between cells and various messenger systems, divided into three phases: inflammatory, proliferative, and remodeling (<xref ref-type="bibr" rid="B47">Velnar et al., 2009</xref>).</p>
<p>The results of molecular dynamics provide a detailed and dynamic view of molecular behavior, essential for understanding complex phenomena of molecule-protein binding. Despite the RMSD values of limonoids 3 and 6 being close and many hydrogen bonds being observed for both molecules, the better binding energy was observed for limonoid 3, suggesting that it may be the most promising.</p>
<p>In terms of the dynamics of fatty acids 15 and 16, it was observed that the RMSD of these molecules was lower than that of LUR. However, there was a slight difference between the number of hydrogen bonds and the energy, with compound 15 being the most promising.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>5 Conclusion</title>
<p>In summary, the leishmanicidal effect of <italic>C. guianensis</italic> appears to result from the synergistic effect between limonoids and fatty acids. Limonoids have an antiparasitic effect, while fatty acids may contribute to the wound healing process of American cutaneous leishmaniasis. Another relevant point is related to mutagenicity, with only fatty acids presenting this potential, while limonoids act as protectors against mutagenic processes. Therefore, <italic>C. guianensis</italic> oil seems to be very promising for the treatment of cutaneous leishmaniasis.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s7">
<title>Ethics statement</title>
<p>The manuscript presents research on animals that do not require ethical approval for their study.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>RCB: Formal Analysis, Investigation, Methodology, Software, Writing&#x2013;original draft, Writing&#x2013;review and editing. RAC: Formal Analysis, Methodology, Software, Writing&#x2013;review and editing. SDPF: Data curation, Investigation, Writing&#x2013;review and editing. KCOA: Data curation, Investigation, Writing&#x2013;review and editing. AMRM: Data curation, Investigation, Writing&#x2013;review and editing. MBC: Supervision, Writing&#x2013;review and editing. PSBM: Data curation, Investigation, Writing&#x2013;review and editing. MFD: Supervision, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The authors declare that financial support was received for the research, authorship, and/or publication of this article. The Dean of Research and Postgraduate Studies at the State University of Par&#x00e1; provided payment for the processing and publication of this article - Notice 02/2023 - PAPQ/PROPESP. Additionally, FAPESPA/CAPES provided support through the program &#x201c;PDPG Strategic Partnerships in States III (PDPG-FAPIII),&#x201d; which supports the first author as a FAPESPA/CAPES-BRAZIL Fellow.</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aguiar</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Leishmaniose visceral no Brasil: artigo de revis&#xe3;o</article-title>. <source>Revista Unimontes Cient&#xed;fica</source> <volume>19</volume> (<issue>1</issue>), <fpage>192</fpage>&#x2013;<lpage>204</lpage>.</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambrozin</surname>
<given-names>A. R. P.</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>F. C.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Bueno</surname>
<given-names>O. C.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Limonoids from andiroba oil and Cedrela fissilis and their insecticidal activity</article-title>. <source>J. Braz. Chem. Soc.</source> <volume>17</volume> (<issue>3</issue>). <pub-id pub-id-type="doi">10.1590/s0103-50532006000300017</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ames</surname>
<given-names>B. N.</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yamasaki</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1975</year>). <article-title>Methods for detecting carcinogens and mutagens with the salmonella/mammalian-microsome mutagenicity test</article-title>. <source>Mutat. Research-Environmental Mutagen. Relat. Subj.</source> <volume>31</volume> (<issue>6</issue>), <fpage>347</fpage>&#x2013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1016/0165-1161(75)90046-1</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>L. H.</given-names>
</name>
</person-group> (<year>2017</year>). <source>Sensibilidade do M&#xe9;todo de Ensaios de Toxicidade Aguda com Embri&#xf5;es de Peixes na Avalia&#xe7;&#xe3;o de Efluente de Ind&#xfa;stria Metalmec&#xe2;nica</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.lume.ufrgs.br/handle/10183/180460">https://www.lume.ufrgs.br/handle/10183/180460</ext-link>
</comment>.</citation>
</ref>
<ref id="B5">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Bitencourt-Ferreira</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>de Azevedo</surname>
<given-names>W. F.</given-names>
</name>
</person-group> (<year>2019</year>). <source>Molegro Virtual Docker for Docking, em Methods in Molecular Biology</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer New York</publisher-name>, <fpage>149</fpage>&#x2013;<lpage>167</lpage>.</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nowlin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Identification of Cys255 in HIF-1&#x3b1; as a novel site for development of covalent inhibitors of HIF-1&#x3b1;/ARNT PasB domain protein-protein interaction: covalent Allosteric Inhibitors of HIF-1&#x3b1;/ARNT PasB PPI</article-title>. <source>Protein Sci. A Publ. Protein Soc.</source> <volume>21</volume> (<issue>12</issue>), <fpage>1885</fpage>&#x2013;<lpage>1896</lpage>. <pub-id pub-id-type="doi">10.1002/pro.2172</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Case</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Aktulga</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Belfon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cerutti</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Cisneros</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Cruzeiro</surname>
<given-names>V. W. D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>AmberTools</article-title>. <source>J. Chem. Inf. Model.</source> <volume>63</volume> (<issue>20</issue>), <fpage>6183</fpage>&#x2013;<lpage>6191</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.3c01153</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chagas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kallahan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>H. P. d. S.</given-names>
</name>
<name>
<surname>Dolabela</surname>
<given-names>M. F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Estudo <italic>in silico</italic> de compostos fen&#xf3;licos isolados de Inga laurina</article-title>. <source>Res. Soc. Dev.</source> <volume>11</volume> (<issue>2</issue>), <fpage>e24511225592</fpage>. <pub-id pub-id-type="doi">10.33448/rsd-v11i2.25592</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Broccatelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Plise</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cheong</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Evaluating the utility of canine Mdr1 knockout Madin-Darby canine kidney I cells in permeability screening and efflux substrate determination</article-title>. <source>Mol. Pharm.</source> <volume>15</volume> (<issue>11</issue>), <fpage>5103</fpage>&#x2013;<lpage>5113</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00688</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Olivi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Botta</surname>
<given-names>C. M. R.</given-names>
</name>
<name>
<surname>Espindola</surname>
<given-names>E. L. G.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>A toxicidade em ambientes aqu&#xe1;ticos: discuss&#xe3;o e m&#xe9;todos de avalia&#xe7;&#xe3;o</article-title>. <source>Quimica nova</source> <volume>31</volume> (<issue>7</issue>), <fpage>1820</fpage>&#x2013;<lpage>1830</lpage>. <pub-id pub-id-type="doi">10.1590/s0100-40422008000700038</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Costa</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>da Rocha</surname>
<given-names>J. A. P.</given-names>
</name>
<name>
<surname>Pinheiro</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>da Rocha</surname>
<given-names>E. C. M.</given-names>
</name>
<name>
<surname>Josino</surname>
<given-names>L. P. C.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>
<italic>In silico</italic> identification of novel allosteric inhibitors of Dengue virus NS2B/NS3 serine protease</article-title>. <source>J. Serbian Chem. Soc.</source> <volume>87</volume> (<issue>6</issue>), <fpage>693</fpage>&#x2013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.2298/jsc210929011d</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Da Silva Miranda</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Cardoso Salazar</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Gomes Coelho</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Predi&#xe7;&#xe3;o <italic>in silico</italic> da atividade antiviral e avalia&#xe7;&#xe3;o de caracter&#xed;sticas farmacocin&#xe9;ticas e toxicol&#xf3;gicas de compostos presentes no &#xf3;leo essencial de Petiveria alliacea L</article-title>. <source>Rev. Casos Consult.</source> <volume>13</volume> (<issue>1</issue>), <fpage>e30705</fpage>.</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degrossoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bosetto</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>C. B. C.</given-names>
</name>
<name>
<surname>Giorgio</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Expression of hypoxia-inducible factor 1&#x3b1; in mononuclear phagocytes infected with Leishmania amazonensis</article-title>. <source>Immunol. Lett.</source> <volume>114</volume> (<issue>2</issue>), <fpage>119</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.imlet.2007.09.009</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="book">
<collab>Discovery Studio Visualizer Dassault Syst&#xe8;mes BIOVIA</collab> (<year>2021</year>). <source>Discovery Studio modeling environment, version 2021</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Dassault Syst&#xe8;mes</publisher-name>.</citation>
</ref>
<ref id="B15">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2024</year>). <source>Home-ADMElab: ADMET Prediction, Scbdd.com</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://admet.scbdd.com/">https://admet.scbdd.com/</ext-link>
</comment>.</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolinsky</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Czodrowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Klebe</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations</article-title>. <source>Nucleic acids Res.</source> <volume>35</volume> (<issue>Web Server</issue>), <fpage>W522</fpage>&#x2013;<lpage>W525</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkm276</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drwal</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dunkel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wettig</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Preissner</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>ProTox: a web server for the <italic>in silico</italic> prediction of rodent oral toxicity</article-title>. <source>Nucleic acids Res.</source> <volume>42</volume> (<issue>Web Server issue</issue>), <fpage>W53</fpage>&#x2013;<lpage>W58</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku401</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ruymgaart</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>e Hess</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>SHAKE parallelization</article-title>. <source>Eur. Phys. J. Special Top.</source> <volume>200</volume> (<issue>1</issue>), <fpage>211</fpage>&#x2013;<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1140/epjst/e2011-01525-9</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falci</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Pasqualotto</surname>
<given-names>A. C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Anfotericina B: uma revis&#xe3;o sobre suas diferentes formula&#xf5;es, efeitos adversos e toxicidade</article-title>. <source>Clin. Biomed. Res.</source> <volume>35</volume> (<issue>2</issue>), <fpage>65</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.4322/2357-9730.56021</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilhermino</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Diamantino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>A. M. V. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Acute toxicity test with Daphnia magna: an alternative to mammals in the prescreening of chemical toxicity?</article-title> <source>Ecotoxicol. Environ. Saf.</source> <volume>46</volume> (<issue>3</issue>), <fpage>357</fpage>&#x2013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1006/eesa.2000.1916</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorgensen</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Chandrasekhar</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Madura</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Impey</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Comparison of simple potential functions for simulating liquid water</article-title>. <source>J. Chem. Phys.</source> <volume>79</volume> (<issue>2</issue>), <fpage>926</fpage>&#x2013;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1063/1.445869</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X. J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Preliminary verification of the anti-hypoxia mechanism of Gentiana straminea maxim based on UPLC-triple TOF MS/MS and network pharmacology</article-title>. <source>BMC Complementary Med. Ther.</source> <volume>22</volume> (<issue>1</issue>), <fpage>310</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-022-03773-0</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>T.-S.</given-names>
</name>
<name>
<surname>Cerutti</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Mermelstein</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>LeGrand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>T. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>GPU-accelerated molecular dynamics and free energy methods in Amber18: Performance enhancements and new features</article-title>. <source>J. Chem. Info. Mod.</source> <volume>58</volume> (<issue>10</issue>), <fpage>2043</fpage>&#x2013;<lpage>2050</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00462</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipinski</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Lead- and drug-like compounds: the rule-of-five revolution</article-title>. <source>Drug Discov. Today Technol.</source> <volume>1</volume> (<issue>4</issue>), <fpage>337</fpage>&#x2013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loureiro</surname>
<given-names>A. P. M.</given-names>
</name>
<name>
<surname>Di Mascio</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Medeiros</surname>
<given-names>M. H. G.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Forma&#xe7;&#xe3;o de adutos exoc&#xed;clicos com bases de DNA: implica&#xe7;&#xf5;es em mutag&#xea;nese e carcinog&#xea;nese</article-title>. <source>Quimica nova</source> <volume>25</volume> (<issue>5</issue>), <fpage>777</fpage>&#x2013;<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1590/s0100-40422002000500014</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maier</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kasavajhala</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wickstrom</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Simmerling</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title>. <source>J. Chem. theory Comput.</source> <volume>11</volume> (<issue>8</issue>), <fpage>3696</fpage>&#x2013;<lpage>3713</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Frasca</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Scherrer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Henao-Mart&#xed;nez</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramanan</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>A review of leishmaniasis: current knowledge and future directions</article-title>. <source>Curr. Trop. Med. Rep.</source> <volume>8</volume> (<issue>2</issue>), <fpage>121</fpage>&#x2013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1007/s40475-021-00232-7</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Marvin</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2023</year>). <source>Chemaxon com</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://marvinjs-demo.chemaxon.com/latest/demo.html">https://marvinjs-demo.chemaxon.com/latest/demo.html</ext-link>.</comment>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kikuchi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Muraoka</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Carapanolides J&#x2013;L from the seeds of Carapa guianensis (andiroba) and their effects on LPS-activated NO production</article-title>. <source>Mol. (Basel, Switz.)</source> <volume>19</volume> (<issue>11</issue>), <fpage>17130</fpage>&#x2013;<lpage>17140</lpage>. <pub-id pub-id-type="doi">10.3390/molecules191117130</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGwire</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Satoskar</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Leishmaniasis: clinical syndromes and treatment</article-title>. <source>QJM Mon. J. Assoc. Physicians</source> <volume>107</volume> (<issue>1</issue>), <fpage>7</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1093/qjmed/hct116</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miranda J&#xfa;nior</surname>
<given-names>R. N. C.</given-names>
</name>
<name>
<surname>Dolabela</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>P&#xf3;voa</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Maia</surname>
<given-names>J. G. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Antiplasmodial activity of the andiroba (Carapa guianensis Aubl., Meliaceae) oil and its limonoid-rich fraction</article-title>, <source>J. ethnopharm.</source> <volume>142</volume> (<issue>3</issue>), <fpage>679</fpage>&#x2013;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2012.05.037</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gohlke</surname>
<given-names>B. O.</given-names>
</name>
<name>
<surname>Erehman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Goede</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>SuperPred: update on drug classification and target prediction</article-title>. <source>Nucleic acids Res.</source> <volume>42</volume> (<issue>W1</issue>), <fpage>W26</fpage>&#x2013;<lpage>W31</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku477</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Boyle</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Banck</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vandermeersch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>G. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Open Babel: an open chemical toolbox</article-title>. <source>J. cheminformatics</source> <volume>3</volume> (<issue>1</issue>), <fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira</surname>
<given-names>I. D. S.</given-names>
</name>
<name>
<surname>Moragas Tellis</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Chagas</surname>
<given-names>M. d. S.</given-names>
</name>
<name>
<surname>Behrens</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Abreu-Silva</surname>
<given-names>A. L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Carapa guianensis aublet (andiroba) seed oil: chemical composition and antileishmanial activity of limonoid-rich fractions</article-title>. <source>BioMed Res. Int.</source> <volume>2018</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2018/5032816</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2008</year>). <source>Effect of oleic and linoleic acids on the inflammatory phase of wound healing in rats. Cell Biochemistry and Function: Cellular biochemistry and its modulation by active agents or disease</source>, <fpage>197</fpage>&#x2013;<lpage>204</lpage>.</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname>
<given-names>H. G.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Accuracy and efficiency of the particle mesh Ewald method</article-title>, <source>J. chem. phy.</source> <volume>103</volume> (<issue>9</issue>), <fpage>3668</fpage>&#x2013;<lpage>3679</lpage>. <pub-id pub-id-type="doi">10.1063/1.470043</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1963</year>). <source>Caracter&#xed;sticas f&#xed;sico-qu&#xed;micas e outras informa&#xe7;&#xf5;es sobre as principais oleaginosas do Brasil</source>.</citation>
</ref>
<ref id="B38">
<citation citation-type="book">
<collab>Preadmet</collab> (<year>2020</year>). <source>ADME TOX calculatio Recuperado de</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://preadmet.bmdrc.kr.Recuperadode.program">http://preadmet.bmdrc.kr.Recuperadode.program</ext-link>.</comment>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodrigues</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Hueb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>T. A. R. R.</given-names>
</name>
<name>
<surname>Fontes</surname>
<given-names>C. J. F.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Fatores associados ao insucesso do tratamento da leishmaniose cut&#xe2;nea com antimoniato de meglumina</article-title>. <source>Rev. Soc. Bras. Med. Trop.</source> <volume>39</volume> (<issue>2</issue>), <fpage>139</fpage>&#x2013;<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1590/s0037-86822006000200001</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roe</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Cheatham</surname>
<given-names>T. E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data</article-title>. <source>J. Chem. theory Comput.</source> <volume>9</volume> (<issue>7</issue>), <fpage>3084</fpage>&#x2013;<lpage>3095</lpage>. <pub-id pub-id-type="doi">10.1021/ct400341p</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salgado</surname>
<given-names>H. L. C.</given-names>
</name>
<name>
<surname>Ndash</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Concei</surname>
<given-names>L. Z. K. M.</given-names>
</name>
<name>
<surname>Catvelho</surname>
<given-names>A. N. S. C.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Enzymatic hydrolysis of crude oil and isolated acyglycerides from Andiroba&#x2019;s seed</article-title>. <source>Int. J. Sci.</source> <volume>7</volume>, <fpage>132</fpage>&#x2013;<lpage>134</lpage>.</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Oliveira</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Figueiredo</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Isolation of Limonoids from seeds of Carapa guianensis Aublet (Meliaceae) by high-speed countercurrent chromatography</article-title>. <source>Phytochem. Anal.</source> <volume>20</volume> (<issue>1</issue>), <fpage>77</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1002/pca.1100</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>L. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Propriedades f&#xed;sico-qu&#xed;micas e perfil dos &#xe1;cidos graxos do &#xf3;leo da andiroba</article-title>. <source>Nativa</source> <volume>6</volume> (<issue>2</issue>), <fpage>147</fpage>. <pub-id pub-id-type="doi">10.31413/nativa.v6i2.4729</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sanjay</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thareja</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1&#x3b1; inhibitors</article-title>. <source>J. Biomol. Struct. Dyn.</source> <volume>41</volume> (<issue>8</issue>), <fpage>3524</fpage>&#x2013;<lpage>3541</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2022.2051745</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tappin</surname>
<given-names>M. R. R.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Siani</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Lucchetti</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Development of an HPLC method for the determination of tetranortriterpenoids in Carapa guianensis seed oil by experimental design</article-title>. <source>J. Pharm. Biomed. Analysis</source> <volume>48</volume> (<issue>4</issue>), <fpage>1090</fpage>&#x2013;<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpba.2008.08.027</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsukamoto</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Guianofruits C-I from fruit oil of andiroba (Carapa guianensis, Meliaceae)</article-title>. <source>Tetrahedron</source> <volume>75</volume> (<issue>9</issue>), <fpage>1149</fpage>&#x2013;<lpage>1156</lpage>.</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velnar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>T. e.</given-names>
</name>
<name>
<surname>Smrkolj</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The wound healing process: an overview of the cellular and molecular mechanisms</article-title>. <source>J. Int. Med. Res.</source> <volume>37</volume> (<issue>5</issue>), <fpage>1528</fpage>&#x2013;<lpage>1542</lpage>. <pub-id pub-id-type="doi">10.1177/147323000903700531</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Caldwel</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Kollman</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2004</year>) <article-title>Development and testing of a general amber force field</article-title>, <source>J. Comp. Chem.</source> <volume>25</volume> (<issue>9</issue>), p. <fpage>1157</fpage>&#x2013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20035</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zucker</surname>
<given-names>E. H.</given-names>
</name>
</person-group> (<year>1985</year>). <article-title>Hazard Evaluation Division-Standard evaluation procedure-acute test for freshwater fish</article-title>. <source>U.S. EPA Publ.</source> <volume>540</volume> (<issue>9</issue>).</citation>
</ref>
</ref-list>
</back>
</article>